185 related articles for article (PubMed ID: 38127261)
1. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies.
Fredman D; McNeil R; Eldar O; Leader A; Gafter-Gvili A; Avni T
J Thromb Thrombolysis; 2024 Mar; 57(3):453-465. PubMed ID: 38127261
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
3. Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer: A Systematic Review and Meta-Analysis.
Fujisaki T; Sueta D; Yamamoto E; Buckley C; Sacchi de Camargo Correia G; Aronson J; Tallón de Lara P; Fujisue K; Usuku H; Matsushita K; Mehran R; Dangas GD; Tsujita K
JACC CardioOncol; 2024 Feb; 6(1):99-113. PubMed ID: 38510285
[TBL] [Abstract][Full Text] [Related]
4. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.
Vasanthamohan L; Boonyawat K; Chai-Adisaksopha C; Crowther M
J Thromb Haemost; 2018 Jul; 16(7):1288-1295. PubMed ID: 29772108
[TBL] [Abstract][Full Text] [Related]
5. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
[TBL] [Abstract][Full Text] [Related]
6. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
7. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of apixaban versus vitamin K antagonists in patients undergoing dialysis: a systematic review and meta-analysis.
Zhang Y; Wang J; Shen N; Jiang J; Xie Y
Ren Fail; 2024 Dec; 46(1):2349114. PubMed ID: 38770962
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
10. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
Al Said S; Alabed S; Kaier K; Tan AR; Bode C; Meerpohl JJ; Duerschmied D
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD013252. PubMed ID: 31858590
[TBL] [Abstract][Full Text] [Related]
11. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin.
Lawal OD; Aronow HD; Hume AL; Shobayo F; Matson KL; Barbour M; Zhang Y; Wen X
Res Pract Thromb Haemost; 2024 Jan; 8(1):102293. PubMed ID: 38268519
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis.
Sindet-Pedersen C; Pallisgaard JL; Olesen JB; Gislason GH; Arevalo LC
Thromb Res; 2015 Oct; 136(4):732-8. PubMed ID: 26277682
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
Elsebaie MAT; van Es N; Langston A; Büller HR; Gaddh M
J Thromb Haemost; 2019 Apr; 17(4):645-656. PubMed ID: 30690830
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
van der Hulle T; Kooiman J; den Exter PL; Dekkers OM; Klok FA; Huisman MV
J Thromb Haemost; 2014; 12(3):320-8. PubMed ID: 24330006
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world.
Aryal MR; Gosain R; Donato A; Yu H; Katel A; Bhandari Y; Dhital R; Kouides PA
Blood Adv; 2019 Aug; 3(15):2381-2387. PubMed ID: 31405948
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis.
Almajdi A; Almutairi S; Alharbi M
Thromb Res; 2023 Sep; 229():77-85. PubMed ID: 37419006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
